All Drugs and Chemicals

Antineoplastic Agents

Antibodies

Antibodies, Monoclonal

Immunoglobulins

Endothelial Growth Factors

Mitogens

Ramucirumab

Angiogenesis Inhibitors

Growth Inhibitors

All patients will receive intravenous infusions of IMC-1121B with the dose depending on which cohort they are enrolled into. A minimum of three patients will be enrolled in each cohort.

A completed patient will be either a patient who completes the 4-week treatment cycle and 2-week observation period (for a total of 6 weeks), or a patient who discontinues therapy for an IMC-1121B-related toxicity. Toxicity data for each cohort will be reviewed prior to dose escalation.

When all patients complete a cohort, dose escalation to the next cohort will occur.

Cohort 1

2 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.

IMC-1121B

Cohort 2

4 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.

1121B

Cohort 3

6 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.

Cohort 4

8 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.

Cohort 5

10 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.

Cohort 6

13 mg/kg once a week for 4 weeks, followed by a 2-week observation period.

Cohort 7

16 mg/kg once a week for 4 weeks, followed by a 2-week observation period.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

The purpose of this study is to determine if IMC-1121B is safe for patients, and to determine the best dose of IMC-1121B to give to patients.

The purpose of this study is to establish the safety profile and the maximum tolerated dose (MTD) of the anti-VEGFR-2 monoclonal antibody IMC-1121B administered weekly in patients with advanced solid tumors who have not responded to standard therapy or for whom no standard therapy is available.

Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy

Phase I Study of Weekly Anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Monoclonal Antibody IMC-1121B in Patients With Advanced Solid Tumors Who Have Not Responded to Standard Therapy

Eli Lilly and Company

Pharmaceutical Solutions

IMC-1121B injectable solution at a concentration of 5 mg/mL in single-use vials containing 100 mg/20 mL or 250 mg/50 mL of product, administered intravenously at an initial dose of 6 mg/kg.A minimum of three patients will be enrolled into each cohort. When all patients complete a cohort, dose escalation to the next cohort will occur.

Cohort 1

6 mg/kg I.V., once every other week for 4 weeks

Cohort 2

8mg/kg I.V., once every other week for 4 weeks

Cohort 3

10 mg/kg I.V., once every other week for 4 weeks

Cohort 4

15 mg/kg I.V., once every 3 weeks for 6 weeks

Cohort 5

20 mg/kg I.V., once every 3 weeks for 6 weeks

We are conducting a research study for tumors that have not responded to prior treatment. The subject will receive an investigational drug called IMC-1121B. ImClone LLC, the maker of IMC-1121B, is running this research study.

We believe that IMC-1121B blocks the growth factors made by the cancer cells, so new blood vessels do not grow. It is believed that without the new blood vessels, the cancer or tumor will not get the oxygen and food that it needs to grow. This may stop the cancer from growing or spreading and the tumor cells may die. Since normal blood vessels have already formed in adults, it might be possible to stop tumor growth without harming normal cells.

We are conducting a research study for tumors that have not responded to prior treatment. The subject will receive an investigational drug called IMC-1121B. ImClone LLC, the maker of IMC-1121B, is running this research study.

In order for a cancer to grow, it needs blood vessels to bring to it oxygen and food. Cancer cells can make growth factors that cause the abnormal growth of new blood vessels. This is called angiogenesis. Normally, new blood vessels do not grow in adults. Angiogenesis inhibitors are drugs that may prevent abnormal growth of blood vessels to tumors. IMC-1121B is an angiogenesis inhibitor. We believe that IMC-1121B blocks the growth factors made by the cancer cells, so new blood vessels do not grow. It is believed that without the new blood vessels, the cancer or tumor will not get the oxygen and food that it needs to grow. This may stop the cancer from growing or spreading and the tumor cells may die. Since normal blood vessels have already formed in adults, it might be possible to stop tumor growth without harming normal cells.

Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy

Phase 1 Study of Every Other Week Anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Monoclonal Antibody IMC-1121B in Patients With Advanced Solid Tumors Who Have Not Responded To Standard Therapy

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy	NCT00793975	Advanced Solid ...	IMC-1121B 1121B 1121B 1121B 1121B 1121B 1121B	18 Years -	Eli Lilly and Company
Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy	NCT00793975	Advanced Solid ...	IMC-1121B 1121B 1121B 1121B 1121B 1121B 1121B	18 Years -	Eli Lilly and Company
Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy	NCT00793975	Advanced Solid ...	IMC-1121B 1121B 1121B 1121B 1121B 1121B 1121B	18 Years -	Eli Lilly and Company
Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy	NCT00786383	Cancer	IMC-1121B 1121B 1121B 1121B 1121B	18 Years -	Eli Lilly and Company

Spots Global Cancer Trial Database for 1121b

Every month we try and update this database with for 1121b cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for 1121b

Every month we try and update this database with for 1121b cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for 1121b cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.